Cadrenal Therapeutics, Inc. Common Stock (CVKD)
$
12.68
-0.24 (-1.89%)
Key metrics
Financial statements
Free cash flow per share
-5.9506
Market cap
26 Million
Price to sales ratio
12.2 Thousand
Debt to equity
0
Current ratio
3.5558
Income quality
0.8270
Average inventory
0
ROE
-1.9640
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company focused on advancing its innovative therapy, Tecarfarin, which has received orphan drug designation for preventing systemic thromboembolism of cardiac origin in patients suffering from end-stage renal disease and atrial fibrillation. The company was established in 2022 and is based in Ponte Vedra, Florida. In its financial performance, the net total of other income and expenses is $309,251.00 reflecting non-core financial activities that could impact overall profitability. The income before tax ratio stands at 0.00 indicating the pre-tax margin achieved by the company during its operations. Investors will find that the company's stock is identified with the symbol 'CVKD' in the market, providing a straightforward way to track its performance. Additionally, the diluted EPS is -$8.73 which takes into account any potential share dilution that might affect earnings per share. It is noteworthy that the company incurred an interest expense of $0.00 which reflects its commitments to debt servicing and can influence cash flow management. Looking at the investment landscape, the stock is affordable at $12.50 making it suitable for budget-conscious investors who are exploring opportunities in the biopharmaceutical sector. However, it exhibits a low average trading volume of 28,762.00 indicating lower market activity which may impact liquidity and volatility. With a market capitalization of $25,954,109.00 the company is classified as a small-cap player within its industry. Cadrenal is a key player in the Biotechnology industry, where it contributes significantly to the overall market landscape by driving innovation and therapeutic advancements. Furthermore, it belongs to the Healthcare sector, a vital part of the economy, and is dedicated to fostering growth and development in its field.
Is Cadrenal Therapeutics, Inc. Common Stock (CVKD) a good investment?
Investing in Cadrenal Therapeutics, Inc. Common Stock (CVKD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Cadrenal Therapeutics, Inc. Common Stock (CVKD)'s stock forecast?
Analysts predict Cadrenal Therapeutics, Inc. Common Stock stock to fluctuate between $5.70 (low) and $22.90 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cadrenal Therapeutics, Inc. Common Stock's market capitalization?
As of 2025-08-18, Cadrenal Therapeutics, Inc. Common Stock's market cap is $25,954,109, based on 2,046,854 outstanding shares.
How does Cadrenal Therapeutics, Inc. Common Stock compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cadrenal Therapeutics, Inc. Common Stock has a Lower Market-Cap, indicating a difference in performance.
How can I buy Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock?
To buy Cadrenal Therapeutics, Inc. Common Stock (CVKD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CVKD. Place an order (Market, Limit, etc.).
What is the best time to invest in Cadrenal Therapeutics, Inc. Common Stock?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Cadrenal Therapeutics, Inc. Common Stock stock ever split?
Cadrenal Therapeutics, Inc. Common Stock's last stock split was 1:15 on 2024-08-20.
How did Cadrenal Therapeutics, Inc. Common Stock perform in the last earnings report?
Revenue: $0 | EPS: -$8.73 | Growth: -9.35%.
Where can I find Cadrenal Therapeutics, Inc. Common Stock's investor relations reports?
Visit https://www.cadrenal.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cadrenal Therapeutics, Inc. Common Stock?
You can explore historical data from here
What is the all-time high and low for Cadrenal Therapeutics, Inc. Common Stock stock?
All-time high: $101.25 (2023-01-20) | All-time low: $5.40 (2024-04-10).
What are the key trends affecting Cadrenal Therapeutics, Inc. Common Stock stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
8 days ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.
businesswire.com
14 days ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis.
businesswire.com
3 months ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #ESKD--Cadrenal announces manufacturing and supply chain milestones for its lead drug, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant.
businesswire.com
3 months ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update.
businesswire.com
4 months ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics to present at inaugural Centri Capital Conference at Nasdaq on April 22, 2025.
businesswire.com
7 months ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior.
businesswire.com
8 months ago
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as a superior and safer chronic anticoagulant therapy for warfarin-dependent patients with implanted cardiac devices including left ventricular assist devices (LVAD) or for those with rare cardiovascular conditions. “This year has marked significant opportunities and advancements for Cadrenal Therape.
prnewswire.com
9 months ago
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla. , Nov. 19, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has been recognized as the 2024 "Anticoagulation Therapy Company of the Year" by Pharma Tech Outlook, an industry publication focused on breakthrough pharmaceutical technologies.
prnewswire.com
9 months ago
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla. , Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit that featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3) left ventricular assist device (LVAD).
prnewswire.com
9 months ago
PONTE VEDRA, Fla. , Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and superior anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.
See all news
